Argenx Se (ARGX) Non Operating Income (2019 - 2021)
Argenx Se's (ARGX) quarterly Non Operating Income came in at -$420000.0 in Q1 2021, up 88.3% on a YoY basis from -$223043.5 in Q1 2020, and down 230.95% quarter-over-quarter from $320726.0 in Q4 2020.
Analysis
Argenx Se (ARGX) Non Operating Income (2019 - 2021) Analysis & Trends
Argenx Se (ARGX) has reported Non Operating Income for 3 consecutive years, with -$420000.0 the latest figure, recorded in Q1 2021.
- For the quarter ending Q1 2021, Non Operating Income rose 88.3% year-over-year to -$420000.0; the trailing twelve-month figure through Mar 2021 stood at $168336.4 (changed N/A YoY), and the FY2021 full-year result was -$944000.0, up 37.11% from the prior year.
- Non Operating Income retreated to -$420000.0 in Q1 2021 per ARGX's latest filing, from $320726.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $3.9 million in Q4 2019 and bottomed at -$3.6 million in Q1 2020.
- Historically, Non Operating Income has averaged $42084.1 across 3 years, with a median of -$49637.0 in 2021.
- The sharpest annual moves came in 2020 and 2021: Non Operating Income plunged 91.69% in 2020, then surged 88.3% in 2021.
- Over 3 years, Non Operating Income stood at $3.9 million in 2019, then slumped by 91.69% to $320726.0 in 2020, then slumped by 230.95% to -$420000.0 in 2021.
- According to Business Quant data, Non Operating Income over the past three periods registered -$420000.0, $320726.0, and -$3.6 million for Q1 2021, Q4 2020, and Q1 2020 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | -73.00 Mn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 387.00 Mn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 234.30 Mn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | -53.64 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | - |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | - |
| 10 | BioNTech SE | 26.24 Bn | 12.58 Bn | 10.00 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2021 | -420,000.00 |
| Dec 31, 2020 | 320,725.97 |
| Mar 31, 2020 | -3.59 Mn |
| Dec 31, 2019 | 3.86 Mn |